Investors Notified: Deadline Approaches for Class Action Against Soleno Therapeutics with Potential Losses

Important Shareholder Alert: Soleno Therapeutics

In a recent announcement, ClaimsFiler, a prominent service dedicated to assisting shareholders, has issued an alert specifically for investors in Soleno Therapeutics, Inc. (NasdaqCM: SLNO). This notification is crucial for individuals who have incurred losses exceeding $100,000 during the designated timeframe of March 26, 2025, to November 4, 2025. All affected shareholders are reminded they must take action before the impending deadline of May 5, 2026, to file lead plaintiff applications in the ongoing class action lawsuit.

Overview of the Legal Matter

The lawsuit has been filed in the United States District Court for the Northern District of California, identifying Soleno Therapeutics and several of its executives as defendants. The crux of the case revolves around allegations that these individuals failed to disclose essential information regarding the company's operations and products during the stated class period, which amounts to a violation of federal securities laws.

Allegations Against Soleno Therapeutics

Among the allegations, it is noted that the company’s Phase 3 clinical trial program for its primary product, DCCR—designed for the treatment of hyperphagia in individuals with Prader-Willi syndrome—has raised multiple concerns. Reportedly, the company minimized or misrepresented safety issues related to the drug's administration. This includes indications of excessive fluid retention among participants in clinical trials, potentially leading to serious health risks that have not been adequately communicated.

Furthermore, potential adverse ramifications related to commercial viability and safety concerns may pose additional challenges, such as patient discontinuation and prescriber reluctance after the product's launch. Such claims can have severe implications for the reputation of both Soleno Therapeutics and its leadership.

Filing Your Claim

For shareholders who believe they qualify to be part of this legal action, detailed resources are readily available. ClaimsFiler encourages investors to visit this link to understand the specifics of the case and how they can participate. A toll-free number (844-367-9658) is also provided for further inquiries.

About ClaimsFiler

ClaimsFiler plays a pivotal role in providing essential information to retail investors looking to recover losses associated with securities class action settlements. Their platform allows users to register for free, upload portfolio data, and receive information on relevant cases in which they may be invested. Legal firm Kahn Swick & Foti, LLC is directly involved in offering free consultations for those wishing to discuss their potential case further.

Wrapping up, this shareholder alert serves as a critical reminder for those who have suffered losses linked to Soleno Therapeutics. Taking timely action can be essential in accessing potential recoveries. As the deadline approaches, affected shareholders should act promptly to ensure their interests are represented in this class action lawsuit.